TCI Wealth Advisors’s Arcus Biosciences RCUS Stock Holding History

TCI Wealth Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$37	–	1761
2023 Q1	$37	Sell	2 -2	-50%	-$38	﹤0.01%	2459
2022 Q4	$83	Buy	4 +2	+100%	+$55	﹤0.01%	2405
2022 Q3	$0	Buy	+2	New	+$53	﹤0.01%	2524
2022 Q2	–	Sell	-128	Closed	-$4K	–	2473
2022 Q1	$4K	Sell	128 -3	-2%	-$101	﹤0.01%	1773
2021 Q4	$5K	Buy	131 +28	+27%	+$1.09K	﹤0.01%	1707
2021 Q3	$4K	Buy	+103	New	+$3.21K	﹤0.01%	1806
2021 Q2	–	Sell	-54	Closed	-$2K	–	2434
2021 Q1	$2K	Buy	+54	New	+$1.88K	﹤0.01%	1863

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TCI Wealth Advisors's RCUS Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 2 shares — an estimated $37 sold.

TCI Wealth Advisors first reported a position in RCUS in Q1 2021 and held it in 7 quarters. The position peaked at $5K in Q4 2021. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

TCI Wealth Advisors reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 2 Arcus Biosciences shares in Q2 2023, an estimated $37.
TCI Wealth Advisors first reported a position in Arcus Biosciences in Q1 2021 and held it in 7 quarters.
TCI Wealth Advisors's Arcus Biosciences position peaked at $5K in Q4 2021.
181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.